"instanceType","label","id","text","description","name","uuid:ID"
"Objective","","Objective_1","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","Main objective","OBJ1","15aacce6-2128-4584-8788-85fc63bea192"
"Objective","","Objective_2","To document the safety profile of the xanomeline TTS.","Safety","OBJ2","30c489d2-8ea5-4d26-85e4-812ffc3bf284"
"Objective","","Objective_3","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","Behaviour","OBJ3","cbb39db1-51e0-4d90-bbd0-cdfdcc89bd48"
"Objective","","Objective_4","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","","OBJ4","72c01fbf-9fb6-41f6-bf59-81761d8141ee"
"Objective","","Objective_5","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","","OBJ5","5066d23d-8ba2-4db5-aded-fde98869035a"
"Objective","","Objective_6","To assess the treatment response as a function of Apo E genotype.","","OBJ6","03b94a18-27c8-44d2-bc4f-c3540794d0f4"
